EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Dual Glucagon and GLP ‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Elif I Ekinci iD, Sandra González Maldonado iD, Anna Unseld, Jorge Arrubla Martinez iD, Anita M Hennige iD, Corinna Schoelch iD

Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8242-8253

DOI: 10.1111/dom.70861 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 22.06.2026. Verfasst von Elif I Ekinci und 5 weiteren Autor:innen. Beteiligte Einrichtung: Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Insulin-Secreting Cells, Obesity. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This post hoc analysis evaluated the effect of survodutide on beta‐cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Materials and Methods Trial 1404‐0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks. Trial 1404‐0036 randomised 387 participants with overweight/obesity and normoglycaemia to receive survodutide or placebo for 46 weeks. Descriptive statistics were derived from both trials. Biomarker responses were analysed using mixed models for repeated measures and regression analysis to assess the impact of bodyweight changes.

Results

In trial 1404‐0002, survodutide was associated with significant and rapid increases in HOMA‐β versus placebo, with significant decreases in HOMA‐IR, glucagon, and fasting plasma glucose (FPG). No significant changes occurred in high‐molecular‐weight (HMW) adiponectin, C‐peptide, or fasting insulin levels. In trial 1404‐0036, there was no significant change in HOMA‐β with survodutide versus placebo, likely owing to normoglycaemia in participants. Survodutide was associated with significant decreases in HOMA‐IR, glucagon, C‐peptide, fasting insulin, and FPG versus placebo, and significant increases in HMW adiponectin. Combining all survodutide dose groups for each trial, absolute change in bodyweight from baseline explained the largest proportion of total variability in changes from baseline in fasting insulin and HOMA‐IR. However, it did not explain other changes observed.

Conclusions

Survodutide was associated with significantly improved beta‐cell function and insulin sensitivity in adults with type 2 diabetes and with overweight or obesity. The durability of beta‐cell improvements after treatment cessation remains unknown. These effects were largely independent of bodyweight changes, suggesting additional metabolic benefit beyond weight loss. Trial Registration: Trial 1404‐0002, ClinicalTrials.gov identifier: NCT04153929; EudraCT number: 2019‐002390‐60. Trial 1404‐0036, ClinicalTrials.gov identifier: NCT04667377; EudraCT number: 2020‐002479‐37.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Insulin ResistanceInsulin-Secreting CellsObesityHypoglycemic AgentsOverweightGlucagon-Like Peptide-1 Receptor AgonistsGlucagonPeptide FragmentsHumansFemaleMaleBiomarkersMiddle AgedSemaglutideBlood GlucoseMetforminGlucagon-Like PeptidesAdultDiabesityDouble-Blind MethodDrug Therapy, CombinationAged

Stichwörter der Autor:innen

GLP‐1beta‐cell functionglucagoninsulin sensitivityobesityoverweightsurvodutidetype 2 diabetes

Substanzen

BiomarkersHypoglycemic AgentsSemaglutideBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsGlucagonMetforminGlucagon-Like PeptidesPeptide Fragments

Autor:innen und Institutionen

  • Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Medicine, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
  • Centre for Research and Education in Diabetes and Obesity (CREDO) and Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

ORCID-Profile: Elif I Ekinci, Sandra González Maldonado, Jorge Arrubla Martinez, Anita M Hennige, Corinna Schoelch

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Ekinci, E. I., Maldonado, S. G., Unseld, A., Martinez, J. A., Hennige, A. M., & Schoelch, C. (2026). Dual Glucagon and GLP ‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes, Obesity and Metabolism, 28(9), 8242-8253. https://doi.org/10.1111/dom.70861

Vancouver

Ekinci EI, Maldonado SG, Unseld A, Martinez JA, Hennige AM, Schoelch C. Dual Glucagon and GLP ‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes, Obesity and Metabolism. 2026;28(9):8242-8253. doi:10.1111/dom.70861

BibTeX
@article{Ekinci2026,
  author = {Ekinci, Elif I and Maldonado, Sandra González and Unseld, Anna and Martinez, Jorge Arrubla and Hennige, Anita M and Schoelch, Corinna},
  title = {Dual Glucagon and GLP ‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {9},
  pages = {8242--8253},
  doi = {10.1111/dom.70861}
}
Kostenlos starten →